Moyer VA: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012, 157: 120-134. 10.7326/0003-4819-157-2-201207170-00459.
Article
PubMed
Google Scholar
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012, 366: 981-990. 10.1056/NEJMoa1113135.
Article
PubMed
Google Scholar
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009, 101: 374-383. 10.1093/jnci/djp001.
Article
PubMed
PubMed Central
Google Scholar
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166.
Article
PubMed
Google Scholar
Telesca D, Etzioni R, Gulati R: Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics. 2008, 64: 10-19. 10.1111/j.1541-0420.2007.00825.x.
Article
PubMed
Google Scholar
Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT: The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007, 99: 1171-1177. 10.1093/jnci/djm060.
Article
PubMed
Google Scholar
Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G: Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007, 25: 431-436. 10.1200/JCO.2006.06.9351.
Article
CAS
PubMed
Google Scholar
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L: Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008, 359: 2220-2232. 10.1056/NEJMoa0801869.
Article
CAS
PubMed
Google Scholar
Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H: Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem. 2006, 52: 235-239.
Article
CAS
PubMed
Google Scholar
Vickers AJ, Cronin AM, Bjork T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case–control study. BMJ. 2010, 341: c4521-10.1136/bmj.c4521.
Article
PubMed
PubMed Central
Google Scholar
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006, 98: 529-534. 10.1093/jnci/djj131.
Article
PubMed
Google Scholar
Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H: The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res. 2010, 16: 4374-4381. 10.1158/1078-0432.CCR-10-1328.
Article
CAS
PubMed
PubMed Central
Google Scholar
Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, Zappa M, Tammela TL, Mäkinen T, Carlsson S, Korfage IJ, Essink-Bot ML, Otto SJ, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ: Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012, 367: 595-605. 10.1056/NEJMoa1201637.
Article
CAS
PubMed
Google Scholar
Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL: Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med. 2010, 170: 1256-1261.
Article
PubMed
PubMed Central
Google Scholar
Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ: Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1201-1207. 10.1158/1055-9965.EPI-09-1251.
Article
PubMed
PubMed Central
Google Scholar
Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilja H, Norming U, Hugosson J: Lead time associated with screening for prostate cancer. Int J Cancer. 2004, 108: 122-129. 10.1002/ijc.11554.
Article
PubMed
Google Scholar
Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE: Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol. 2012, 61: 865-874. 10.1016/j.eururo.2011.11.007.
Article
PubMed
Google Scholar
Kuller LH, Thomas A, Grandits G, Neaton JD: Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 373-377.
PubMed
Google Scholar
Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J: Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994, 344: 1594-1598. 10.1016/S0140-6736(94)90405-7.
Article
CAS
PubMed
Google Scholar
Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW: Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010, 116: 4711-4717. 10.1002/cncr.25447.
Article
PubMed
Google Scholar
Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst. 1995, 87: 354-360. 10.1093/jnci/87.5.354.
Article
CAS
PubMed
Google Scholar
Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006, 98: 1521-1527. 10.1093/jnci/djj410.
Article
PubMed
PubMed Central
Google Scholar
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012, 367: 203-213. 10.1056/NEJMoa1113162.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, SPCG-4 Investigators: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011, 364: 1708-1717. 10.1056/NEJMoa1011967.
Article
CAS
PubMed
Google Scholar
Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L: Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol. 2012, 62: 204-209. 10.1016/j.eururo.2012.04.024.
Article
PubMed
PubMed Central
Google Scholar
van Leeuwen PJ, Connolly D, Tammela TL, Auvinen A, Kranse R, Roobol MJ, Schroder FH, Gavin A: Balancing the harms and benefits of early detection of prostate cancer. Cancer. 2010, 116: 4857-4865. 10.1002/cncr.25474.
Article
PubMed
Google Scholar
Welch HG, Albertsen PC: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009, 101: 1325-1329. 10.1093/jnci/djp278.
Article
PubMed
PubMed Central
Google Scholar
Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO: Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012, 104: 1335-1342. 10.1093/jnci/djs299.
Article
PubMed
PubMed Central
Google Scholar
Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB: The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012, 118: 5955-5963. 10.1002/cncr.27594.
Article
PubMed
PubMed Central
Google Scholar